Ftse Mib
36.218,98
0,00%
DAX
21.428,24
-1,30%
S&P 500
5.994,57
-0,76%
NASDAQ
19.391,96
-1,20%
Bitcoin
99.495,65
-1,90%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vaccinex Inc (VCNX) Vaccinex Inc (VCNX) Notizie

VCNX

Vaccinex (VCNX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VCNX
DataOraFonteTitoloSimboloCompagnia
17/12/202415:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VCNXVaccinex Inc
17/12/202415:00GlobeNewswire Inc.Vaccinex Announces Receipt of Delisting Notification from NasdaqNASDAQ:VCNXVaccinex Inc
18/11/202422:15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:VCNXVaccinex Inc
18/11/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VCNXVaccinex Inc
18/11/202414:30GlobeNewswire Inc.Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VCNXVaccinex Inc
14/11/202422:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VCNXVaccinex Inc
14/11/202421:39Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:VCNXVaccinex Inc
07/11/202414:30GlobeNewswire Inc.Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITCNASDAQ:VCNXVaccinex Inc
05/11/202414:30GlobeNewswire Inc.Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer’s Annual MeetingNASDAQ:VCNXVaccinex Inc
31/10/202415:00GlobeNewswire Inc.Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Madrid, SpainNASDAQ:VCNXVaccinex Inc
25/10/202422:11Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:VCNXVaccinex Inc
25/10/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:VCNXVaccinex Inc
24/10/202414:30GlobeNewswire Inc.Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024NASDAQ:VCNXVaccinex Inc
16/10/202422:44Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:VCNXVaccinex Inc
27/09/202422:11Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VCNXVaccinex Inc
18/09/202414:30GlobeNewswire Inc.Vaccinex Announces Exercise of Warrants for $6.2 Million in Gross ProceedsNASDAQ:VCNXVaccinex Inc
14/08/202414:30GlobeNewswire Inc.Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development PartnershipNASDAQ:VCNXVaccinex Inc
31/07/202415:00GlobeNewswire Inc.Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s DiseaseNASDAQ:VCNXVaccinex Inc
17/07/202414:00GlobeNewswire Inc.Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024NASDAQ:VCNXVaccinex Inc
06/06/202414:30GlobeNewswire Inc.Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s DiseaseNASDAQ:VCNXVaccinex Inc
16/05/202400:00GlobeNewswire Inc.Vaccinex Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VCNXVaccinex Inc
14/05/202422:36Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:VCNXVaccinex Inc
10/05/202418:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VCNXVaccinex Inc
08/05/202418:29Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:VCNXVaccinex Inc
02/04/202414:30GlobeNewswire Inc.Vaccinex Reports 2023 Financial Results and Provides Corporate UpdateNASDAQ:VCNXVaccinex Inc
27/03/202413:30GlobeNewswire Inc.Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:VCNXVaccinex Inc
21/02/202414:00GlobeNewswire Inc.Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus TechnologyNASDAQ:VCNXVaccinex Inc
15/02/202414:00GlobeNewswire Inc.Vaccinex, Inc. Announces Reverse Stock SplitNASDAQ:VCNXVaccinex Inc
13/02/202422:15Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:VCNXVaccinex Inc
09/02/202422:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VCNXVaccinex Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VCNX

La tua Cronologia

BIT
11COV
Bearer
BIT
18TRA
Traton
BIT
19MW
Marvell Technology
BIT
1A
Agilent Technologies
BIT
1AA
Alcoa
BIT
1AAD
Amadeus Fire
BIT
1AAG
Aumann
BIT
1AAL
American Airlines
BIT
1AAPL
Apple
BIT
1ABBV
Abbvie
BIT
1ABI
Anheuser Busch InBev SA NV
BIT
1ABNB
Airbnb
BIT
1ACA
Credit Agricole
BIT
1ACS
ACS Actividades de Const...
BIT
1AD
Koninklijke Ahold Delhai...
BIT
1ADBE
Adobe
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci